Skip to content

Clinical effect of topical steroid and/or clarithromycin for CRS medication

Clinical effect of topical steroid and/or clarithromycin for CRS medication

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001234
Enrollment
Unknown
Registered
2011-03-21
Start date
2010-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CRSw/nNP

Interventions

2:Budesonide+Clarithromycin

Sponsors

The first affiliated hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The patient should be voluntary to take part in the trial, understand and agree to take the drugs, accept follow-ups and report the events properly. And the inform consent should be signed; 2. Aged between 18 and 70 years old; 3. Male or female, Chinese people; 4. With the diagnosis of CRSw/nNP according to EP3OS 2007: Subjective objectives: presence of two or more symptoms one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip): +/- facial pain/pressure; +/- reduction or loss of smell; for > 12 weeks; Endoscopy: with/without polyps bilateral in middle meatus, purulent secretionin the middle meatus, with/without middle meatus swelling or mucous block; Image: coronal CT scan, with/without mucous change in OMC/sinus (only for reference).

Exclusion criteria

Exclusion criteria: 1. Allergy to clarithromycin or topical sterouid spray; 2. With any one of the following diseases: cystic fibrosis based on positive sweat test or DNA alleles; gross immunodeficiency (congenital or acquired); congenital mucociliary problems eg primary ciliary dyskinesia (PCD); non-invasive fungal balls and invasive fungal disease; systemic vasculitis and granulomatous diseases; cocaine abuse; neoplasia; 3. Treated with other CRS medicines 4 weeks before inclusion, such as macrolides or steroids; or other treatment, such as nasal lavage or desensitive treatment; 4. Comorbidity with asthma or other gross immunodeficiency, using steroid through the nose or inhalation or systemically; 5. With upper respiratory tract infection; 6. With severe systemic diseases affecting the cardiovascular, metabolic, immunology, neurology, hematology, cerebrovascular or respiratory system; 7. Participate in other clinical researches within the lastest 30 days or the reseacher themselves; 8. With history of psychic disease, or mental problems; 9. Pregnant or breast-feeding females.

Design outcomes

Primary

MeasureTime frame
clinical symtom;

Secondary

MeasureTime frame
endoscopic examination;paranasal sinus CT;

Countries

China

Contacts

Public ContactJianbo SHI
tsjbent@163.com+86 13808884437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026